New Guidance Effective Immediately for Testing of Glycerin, Propylene, Other High Risk Drug Components
Further, the guidance is to provide information on compliance with applicable regulatory requirements and recommendations.
The new guidance from FDA is set to alert pharmaceutical manufacturers, compounders, repackers, and suppliers to the potential public health hazard of glycerin and other high-risk drug components contaminated with diethylene glycol (DEG) or ethylene glycol (EG). This comes from the frequent reports to FDA about fatal poisonings of consumers who ingested drug products in a liquid dosage form, like cough or allergy drug products, that were manufactured using DEG- or EG-contaminated components.
Further, the guidance is to provide information on compliance with applicable regulatory requirements and recommendations to help pharmaceutical manufacturers, repackers, other suppliers of high-risk drug components, and compounders prevent the use of glycerin and other high-risk drug components that are contaminated with DEG or EG.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
